Predictors of seropositivity to human papillomavirus type 53

One of the most prevalent high risk-related cervical human papillomaviruses

Zainab A. Malik, Susan M. Hailpern, Robert D. Burk

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Persistent cervicovaginal infection with high-risk types of HPV is the major risk factor for subsequent cervical neoplasia. HPV53, part of the α6 species group along with HPV types 30, 56, and 66, is one of the most prevalent high risk-related HPV types, yet little is known about the molecular basis of its benign behavior. We generated and utilized HPV53 virus-like particles (VLPs) to investigate risk factors for its seroprevalence in a population of young college women. Seropositivity to HPV53 VLPs was determined using a polymer-based ELISA to measure IgG reactive antibodies. Cervicovaginal cells were collected for HPV DNA detection and typing by MY09/11 PCR. A questionnaire queried for HPV risk factors to estimate odds ratios (ORs). Prevalence of cervicovaginal HPV DNA was 26% (n = 148); 3% of women (n = 17) had HPV53 DNA and 7% (n = 40) were seropositive to HPV53. Seroprevalence of IgG to HPV53 VLPs in women with cervicovaginal HPV53, HPV53-related types (HPV30, 55, and 66), other HPV types, and no HPV was 41%, 11%, 7%, and 6%, respectively (ptrend < 0.001). Risk factors independently associated with HPV53 VLP seropositivity included use of oral contraceptive pills (OCPs) (OR: 4; 95% CI: 1.8, 9), having ≥2 regular partners in the last 6 months (OR: 2.5; 95 % CI: 1.1, 5.8), having a regular male partner with ≥4 lifetime sex partners (OR: 2.6; 95% CI: 1.1 6), seropositivity to HPV16 (OR: 6.7; 95% CI: 3.1, 14.5), and isolation of HPV53 DNA from cervicovaginal lavage (OR: 17.3; 95% CI: 5.3, 55.9). In conclusion, host serological responses to HPV53 VLPs are strongly type-specific, and subjects' risk for HPV53 seropositivity is independently associated with sexual behavior and OCP use.

Original languageEnglish (US)
Pages (from-to)371-377
Number of pages7
JournalViral Immunology
Volume21
Issue number3
DOIs
StatePublished - Sep 1 2008

Fingerprint

Virion
Odds Ratio
Seroepidemiologic Studies
Oral Contraceptives
DNA
Immunoglobulin G
DNA Fingerprinting
Therapeutic Irrigation
Sexual Behavior
Polymers
Enzyme-Linked Immunosorbent Assay
Polymerase Chain Reaction
Antibodies
Infection
Population
Neoplasms

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Predictors of seropositivity to human papillomavirus type 53 : One of the most prevalent high risk-related cervical human papillomaviruses. / Malik, Zainab A.; Hailpern, Susan M.; Burk, Robert D.

In: Viral Immunology, Vol. 21, No. 3, 01.09.2008, p. 371-377.

Research output: Contribution to journalArticle

@article{5aeef06182524b38b0155c05dd9215d4,
title = "Predictors of seropositivity to human papillomavirus type 53: One of the most prevalent high risk-related cervical human papillomaviruses",
abstract = "Persistent cervicovaginal infection with high-risk types of HPV is the major risk factor for subsequent cervical neoplasia. HPV53, part of the α6 species group along with HPV types 30, 56, and 66, is one of the most prevalent high risk-related HPV types, yet little is known about the molecular basis of its benign behavior. We generated and utilized HPV53 virus-like particles (VLPs) to investigate risk factors for its seroprevalence in a population of young college women. Seropositivity to HPV53 VLPs was determined using a polymer-based ELISA to measure IgG reactive antibodies. Cervicovaginal cells were collected for HPV DNA detection and typing by MY09/11 PCR. A questionnaire queried for HPV risk factors to estimate odds ratios (ORs). Prevalence of cervicovaginal HPV DNA was 26{\%} (n = 148); 3{\%} of women (n = 17) had HPV53 DNA and 7{\%} (n = 40) were seropositive to HPV53. Seroprevalence of IgG to HPV53 VLPs in women with cervicovaginal HPV53, HPV53-related types (HPV30, 55, and 66), other HPV types, and no HPV was 41{\%}, 11{\%}, 7{\%}, and 6{\%}, respectively (ptrend < 0.001). Risk factors independently associated with HPV53 VLP seropositivity included use of oral contraceptive pills (OCPs) (OR: 4; 95{\%} CI: 1.8, 9), having ≥2 regular partners in the last 6 months (OR: 2.5; 95 {\%} CI: 1.1, 5.8), having a regular male partner with ≥4 lifetime sex partners (OR: 2.6; 95{\%} CI: 1.1 6), seropositivity to HPV16 (OR: 6.7; 95{\%} CI: 3.1, 14.5), and isolation of HPV53 DNA from cervicovaginal lavage (OR: 17.3; 95{\%} CI: 5.3, 55.9). In conclusion, host serological responses to HPV53 VLPs are strongly type-specific, and subjects' risk for HPV53 seropositivity is independently associated with sexual behavior and OCP use.",
author = "Malik, {Zainab A.} and Hailpern, {Susan M.} and Burk, {Robert D.}",
year = "2008",
month = "9",
day = "1",
doi = "10.1089/vim.2008.0019",
language = "English (US)",
volume = "21",
pages = "371--377",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Predictors of seropositivity to human papillomavirus type 53

T2 - One of the most prevalent high risk-related cervical human papillomaviruses

AU - Malik, Zainab A.

AU - Hailpern, Susan M.

AU - Burk, Robert D.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Persistent cervicovaginal infection with high-risk types of HPV is the major risk factor for subsequent cervical neoplasia. HPV53, part of the α6 species group along with HPV types 30, 56, and 66, is one of the most prevalent high risk-related HPV types, yet little is known about the molecular basis of its benign behavior. We generated and utilized HPV53 virus-like particles (VLPs) to investigate risk factors for its seroprevalence in a population of young college women. Seropositivity to HPV53 VLPs was determined using a polymer-based ELISA to measure IgG reactive antibodies. Cervicovaginal cells were collected for HPV DNA detection and typing by MY09/11 PCR. A questionnaire queried for HPV risk factors to estimate odds ratios (ORs). Prevalence of cervicovaginal HPV DNA was 26% (n = 148); 3% of women (n = 17) had HPV53 DNA and 7% (n = 40) were seropositive to HPV53. Seroprevalence of IgG to HPV53 VLPs in women with cervicovaginal HPV53, HPV53-related types (HPV30, 55, and 66), other HPV types, and no HPV was 41%, 11%, 7%, and 6%, respectively (ptrend < 0.001). Risk factors independently associated with HPV53 VLP seropositivity included use of oral contraceptive pills (OCPs) (OR: 4; 95% CI: 1.8, 9), having ≥2 regular partners in the last 6 months (OR: 2.5; 95 % CI: 1.1, 5.8), having a regular male partner with ≥4 lifetime sex partners (OR: 2.6; 95% CI: 1.1 6), seropositivity to HPV16 (OR: 6.7; 95% CI: 3.1, 14.5), and isolation of HPV53 DNA from cervicovaginal lavage (OR: 17.3; 95% CI: 5.3, 55.9). In conclusion, host serological responses to HPV53 VLPs are strongly type-specific, and subjects' risk for HPV53 seropositivity is independently associated with sexual behavior and OCP use.

AB - Persistent cervicovaginal infection with high-risk types of HPV is the major risk factor for subsequent cervical neoplasia. HPV53, part of the α6 species group along with HPV types 30, 56, and 66, is one of the most prevalent high risk-related HPV types, yet little is known about the molecular basis of its benign behavior. We generated and utilized HPV53 virus-like particles (VLPs) to investigate risk factors for its seroprevalence in a population of young college women. Seropositivity to HPV53 VLPs was determined using a polymer-based ELISA to measure IgG reactive antibodies. Cervicovaginal cells were collected for HPV DNA detection and typing by MY09/11 PCR. A questionnaire queried for HPV risk factors to estimate odds ratios (ORs). Prevalence of cervicovaginal HPV DNA was 26% (n = 148); 3% of women (n = 17) had HPV53 DNA and 7% (n = 40) were seropositive to HPV53. Seroprevalence of IgG to HPV53 VLPs in women with cervicovaginal HPV53, HPV53-related types (HPV30, 55, and 66), other HPV types, and no HPV was 41%, 11%, 7%, and 6%, respectively (ptrend < 0.001). Risk factors independently associated with HPV53 VLP seropositivity included use of oral contraceptive pills (OCPs) (OR: 4; 95% CI: 1.8, 9), having ≥2 regular partners in the last 6 months (OR: 2.5; 95 % CI: 1.1, 5.8), having a regular male partner with ≥4 lifetime sex partners (OR: 2.6; 95% CI: 1.1 6), seropositivity to HPV16 (OR: 6.7; 95% CI: 3.1, 14.5), and isolation of HPV53 DNA from cervicovaginal lavage (OR: 17.3; 95% CI: 5.3, 55.9). In conclusion, host serological responses to HPV53 VLPs are strongly type-specific, and subjects' risk for HPV53 seropositivity is independently associated with sexual behavior and OCP use.

UR - http://www.scopus.com/inward/record.url?scp=51849097391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51849097391&partnerID=8YFLogxK

U2 - 10.1089/vim.2008.0019

DO - 10.1089/vim.2008.0019

M3 - Article

VL - 21

SP - 371

EP - 377

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 3

ER -